Collaborations and partnerships

Alligator conducts its research and development of drug candidates both in its own R&D department and through partnerships with other organizations. We continuously strengthen our position by developing highly innovative and effective drug candidates. To do so, our ambition is to establish long-term strategic and value creating collaborations with the pharma and biotech industry as well as with academic institutions.

Partnerships in research or preclinical development projects may be in the form of inlicensing of immaterial rights or in the form of co-development of drug candidates where costs and future revenues are shared between the parties.

Alligator´s strategy is to develop drug candidates to clinical phase II, but the company may consider outlicensing or co-development partnerships at an earlier phase as well. In August 2015, Alligator closed a license agreement with Janssen Biotech, for global commercialization of ADC-1013. 30 July 2019 Janssen decided to stop further development of the product and Alligator regains all rights for development and commercialization. In July 2017, an agreement was signed with the US biotechnology company Aptevo Therapeutics Inc., for co-development of the bispecific drug candidate ALG.APV-527. Under the terms of the agreement, the parties will jointly own and share equally the development costs associated with advancing this candidate through to the end of phase II clinical development.  

Alligator welcomes opportunities to collaborate with biotech companies as well as academic institutions, for joint development of novel, innovative immunotherapies. We encourage organizations wishing to discuss partnerships related to immaterial rights to novel targets or drug candidates to contact us at